Rosiglitazone (BRL 49653) Enhances Insulin Secretory Response via Phosphatidylinositol 3-Kinase Pathway

Diabetes

Volumn 50, Issue 7-12, 2001, Pages 2598-2602

  Yang, Chi ^a   Chang, Tien Jyun ^b   Chang, Jen Chieh ^a   Liu, Min Wei ^b   Tai, Tong Yuan ^b   Hsu, Walter H ^c   Chuang, Lee Ming ^b,d  

^a NATIONAL CHUNG HSING UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c IOWA STATE UNIVERSITY   (United States)

^d NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; GLUCOSE; INSULIN; PHOSPHATIDYLINOSITOL 3 KINASE; ROSIGLITAZONE; THIAZOLE DERIVATIVE;

ANIMAL; ARTICLE; DOSE RESPONSE; DRUG POTENTIATION; IN VITRO STUDY; MALE; PHYSIOLOGY; RAT; SECRETION; SPRAGUE DAWLEY RAT;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; GLUCOSE; HYPOGLYCEMIC AGENTS; INSULIN; MALE; RATS; RATS, SPRAGUE-DAWLEY; THIAZOLES; THIAZOLIDINEDIONES;

EID: 0035512697     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diabetes.50.11.2598     Document Type: Article

References (31)

1. Chiu KC, Chuang LM: Genetics of type 2 diabetes. J Gen Mol Biol 9:37-68, 1998
2. Lebovitz HE: Insulin mimetic and insulin-sensitizing drugs. Diabetes Res Clin Pract 20:89-91, 1993
3. Saltiel AR, Olefsky JM: Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes 45:1661-1669, 1996
4. Chaiken RL, Eckert-Norton M, Pasmantier R, Boden G, Ryan I, Gelfand RA, Lebovitz HE: Metabolic effects of darglitazone, an insulin sensitizer, in NIDDM patients. Diabetologia 38:1307-1312, 1995
5. Day C: Thiazolidinediones: a new class of antidiabetic drugs. Diabet Med 16:179-192, 1999
6. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA: An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J Biol Chem 270:12953-12956, 1995
7. Willson TM, Cobb JE, Cowan DJ, Wiethe W, Correa ID, Prakash SR, Beck KD, Moore LB, Kliewer SA, Lehmann JM: The structure-activity relationship between peroxisome proliferator-activated receptor gamma agonism and the antihyperglycemic activity of thiazolidinediones. J Med Chem 39:665-668, 1996
8. Berger J, Bailey P, Biswas C, Cullinan CA, Doebber TW, Hayes NS, Saperstein R, Smith RG, Leibowitz MD: Thiazolidinediones produce a conformational change in peroxisomal proliferator-activated receptor-gamma: binding and activation correlate with antidiabetic actions in db/db mice. Endocrinology 137:4189-4195, 1990
9. Whitcomb RW, Saltiel AR: Thiazolidinediones. Expert Opin Invest Drug 4:1299-1309, 1993
10. Grossman SL, Lessem J: Mechanisms and clinical effects of thiazolidinediones. Expert Opin Invest Drug 6:1025-1040, 1997
11. Rieusset J, Auwerx J, Vidal H: Regulation of gene expression by activation of the peroxisome proliferator-activated receptor γ with rosiglitazone (BRL 49653) in human adipocytes. Biochem Biophys Res Commun 265: 265-271, 1999
12. Larrson LI, Boder GB, Shaw WN: Changes in the islets of Langerhans in the obese Zucker rat. Lab Invest 36:593-598, 1977
13. Lemmonier D, Aubert R, Suquet JP, Rosselin G: Metabolism of genetically obese rats on normal or high-fat diet. Diabetologia 10:697-701, 1974
14. Laburthe M, Rancon F, Freychet P, Rosselin G: Glucagon and insulin from lean rats and genetically obese fatty rats: studies by radioimmunoassay, radioreceptor assay and bioassay. Diabetologia 11:517-526, 1975
15. Buckingham RE, Al-Barazanji KA, Nigel Toseland CD, Slaughter M, Connor SC, West A, Bond B, Turner NC, Clapham JC: Peroxisome proliferator-activated receptor-γ agonist, rosiglitazone, protects against nephropathy and pancreatic islet abnormalities in Zucker fatty rats. Diabetes 47:1326-1334, 1998
16. Shimabukuro M, Koyama K, Lee Y, Unger RH: Leptin- or troglitazone-induced lipopenia protects islets from interleukin 1 beta cytotoxicity. J Clin Invest 100:1750-1754, 1997
17. Unger RH: Lipotoxicity in the pathogenesis of obesity-dependent NIDDM: genetics and clinical implications. Diabetes 44:863-870, 1995
18. Lee Y, Hirose H, Ohneda M, Johnson JH, McGarry JD, Unger RH: Beta-cell lipotoxicity in the pathogenesis of non-insulin-dependent diabetes mellitus of obese rats: impairment in adipocyte-beta-cell relationship. Proc Natl Acad Sci U S A 91:10878-10882, 1994
19. Lee Y, Hirose H, Zhou YT, Esser V, McGarry JD, Unger RH: Increased lipogenic capacity of the islets of obese rats: a role in the pathogenesis of NIDDM. Diabetes 46:408-413, 1997
20. Shimabukuro M, Zhou YT, Lee Y, Unger RH: Troglitazone lowers islet fat and restores beta cell function of Zucker diabetic fatty rats. J Biol Chem 273:3547-3550, 1998
21. Higa M, Zhou YT, Ravazzola M, Baetens D, Orci L, Unger RH: Troglitazone prevents mitochondrial alternations, β cell destruction, and diabetes in obese prediabetic rats. Proc Natl Acad Sci U S A 96:11513-11518, 1999
22. Brown KK, Henke BR, Blanchard SG, Cobb JE, Mook R, Kaldor I, Kliewer SA, Lehmann JM, Lenhard JM, Harrington WW, Novak PJ, Faison W, Binz JG, Hashim MA, Oliver WO, Brown HR, Parks DJ, Plunket KD, Tong WQ, Menius JA, Adkison K, Noble SA, Willson TM: A novel N-aryl tyrosine activator of peroxisome proliferator-activated receptor-γ reverses the diabetic phenotype of the Zucker diabetic fatty rat. Diabetes 48:1415-1424, 1999
23. Grodsky GM, Fanska RE: The in vitro perfused pancreas. In Methods in Enzymology, Hormone Action, Pat D. Isolated Cells, Tissues, and Organ Systems. Vol. 39. Hardman JG, O'Malley BW, Eds. New York, Academic, 1975, p. 364-372
24. Hale CN, Randle PJ: Immunoassay of insulin with insulin antibody precipitate. Biochem J 88:137-146, 1963
25. Vlahos CJ, Matter WF, Hui KY, Brown RF: A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H- 1-benzopyran-4-1 (LY294002). J Biol Chem 269:5241-5248, 1994
26. Walker EH, Pacold ME, Perisic O, Stephens L, Hawkins PT, Wymann MP, Williams RL: Structural determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, myricetin, and staurosporine. Mol Cell 6:909-919, 2000
27. Masuda K, Okamoto Y, Tsuura Y, Kato S, Miura T, Tsuda K, Horikoshi H, Ishida H, Seino Y: Effects of troglitazone (CS-045) on insulin secretion in isolated rat pancreatic islets and HIT cells: an insulinotropic mechanism distinct from glibenclamide. Diabetologia 38:24-30, 1995
28. Aspinwall CA, Lakey JRX, Kennedy RT: Insulin-stimulated insulin secretion in single pancreatic beta cells. J Biol Chem 274:6360-6365, 1999
29. 2+ stores in insulin-stimulated insulin secretion in β-cells. J Biol Chem 275:22331-22338, 2000
30. Kim HI, Kim JW, Kim SH, Cha JY, Kim KS, Ahn YH: Identification and functional characterization of the peroxisomal proliferator response element in rat GLUT2 promoter. Diabetes 49:1517-1524, 2000
31. Guillam MT, Dupraz P, Thorens B: Glucose uptake, utilization, and signaling in GLUT2-null islets. Diabetes 49:1485-1491, 2000